Trial · NCT01989754
Adverse events1,294
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 1,294
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Angina Pectoris | Cardiac disorders | Placebo (Placebo) | 33 | 2,903 | |
| serious | Angina Pectoris | Cardiac disorders | Canagliflozin (Experimental) | 22 | 2,904 | |
| serious | Angina Unstable | Cardiac disorders | Placebo (Placebo) | 42 | 2,903 | |
| serious | Angina Unstable | Cardiac disorders | Canagliflozin (Experimental) | 42 | 2,904 | |
| serious | Aortic Valve Disease | Cardiac disorders | Placebo (Placebo) | 1 | 2,903 | |
| serious | Aortic Valve Disease | Cardiac disorders | Canagliflozin (Experimental) | 0 | 2,904 | |
| serious | Aortic Valve Incompetence | Cardiac disorders | Placebo (Placebo) | 1 | 2,903 | |
| serious | Aortic Valve Incompetence | Cardiac disorders | Canagliflozin (Experimental) | 0 | 2,904 | |
| serious | Arrhythmia | Cardiac disorders | Placebo (Placebo) | 1 | 2,903 | |
| serious | Arrhythmia | Cardiac disorders | Canagliflozin (Experimental) | 2 | 2,904 | |
| serious | Arteriosclerosis Coronary Artery | Cardiac disorders | Placebo (Placebo) | 5 | 2,903 | |
| serious | Arteriosclerosis Coronary Artery | Cardiac disorders | Canagliflozin (Experimental) | 3 | 2,904 | |
| serious | Atrial Fibrillation | Cardiac disorders | Placebo (Placebo) | 18 | 2,903 | |
| serious | Atrial Fibrillation | Cardiac disorders | Canagliflozin (Experimental) | 14 | 2,904 | |
| serious | Atrial Flutter | Cardiac disorders | Placebo (Placebo) | 7 | 2,903 | |
| serious | Atrial Flutter | Cardiac disorders | Canagliflozin (Experimental) | 5 | 2,904 | |
| serious | Atrial Tachycardia | Cardiac disorders | Placebo (Placebo) | 0 | 2,903 | |
| serious | Atrial Tachycardia | Cardiac disorders | Canagliflozin (Experimental) | 1 | 2,904 | |
| serious | Atrioventricular Block Complete | Cardiac disorders | Placebo (Placebo) | 1 | 2,903 | |
| serious | Atrioventricular Block Complete | Cardiac disorders | Canagliflozin (Experimental) | 3 | 2,904 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01989754/events?page=2